GCCA
20.2.2024 13:31:29 CET | Business Wire | Press release
A pioneering international programme, which brings together tech start-ups and leading manufacturers in the pursuit of net zero, has launched.
Innovandi Open Challenge 2024 is run by the Global Cement and Concrete Association (GCCA), the industry’s leading international body which is focused on helping the global cement industry reduce its emissions and ultimately achieve net zero concrete.
Applications are being encouraged from start-ups from around the world, interested in working on the development of carbon capture use and storage, for low carbon cement and concrete. Innovative technologies are sought, which include process integrated and end-of-pipe CO2 capture and use, and help prevent the carbon being emitted into the atmosphere.
This will be the 3rd Innovandi Open Challenge and builds on the success of previous years. The first challenge, in 2022, also focused on the development of carbon capture technology, and two start-ups have already gone to pilot stage. The 15 start-ups shortlisted in last year’s 2nd Innovandi Challenge, to work on the development of low carbon concrete, are currently in discussion with manufacturers about forming partnerships.
Claude Loréa, the GCCA’s Cement, Innovation and ESG Director, said: “Our industry is committed to achieving net zero and the development of carbon capture technology is a key part of that work. Our world leading Innovandi Open Challenge programme has already seen remarkable progress being made in just two years, with start-ups and our member companies working together. We’re looking forward to seeing what this year’s applicants can bring, to build on the extensive work that is already underway across the world.”
All GCCA members who account for 80% of global cement production capacity outside of China, and a number of leading Chinese manufacturers, have committed to reaching net zero, by 2050, through the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first global industry to set out such a detailed plan. The GCCA has also recently signed a ground-breaking agreement to work together on decarbonisation with the China Cement Association (CCA).
The development of new technologies is a key part of the industry’s roadmap to net zero, and carbon capture and storage technology is expected to account for around 36% of total emission reductions by 2050.
The industry’s first industrial-scale cement plant equipped with CO2 capture technology is scheduled to be mechanically completed at the Heidelberg Materials site in Brevik, Norway, by the end of 2024, with several more plants expected to open by 2030.
Thomas Guillot, Chief Executive of the GCCA, said: “We already know CCUS technology works, with pilots and projects underway across the world, but it’s crucial to see what other innovations are out there, beyond our industry, that could help accelerate our net zero mission.
“We encourage applications from start-ups around the globe to join us in the urgent fight to limit global warming. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology to further develop CCUS, then you should be applying.”
Jonathan Cool, CEO of Ultra High Materials, a start-up which participated in last year’s Open Challenge, encouraged others to apply: “The support, guidance, exposure to the GCCA membership and the facilitation of collaborative opportunities with GCCA members has been effective, efficient and it's made a beneficial impact for all of us. Given the option to do it all again, we certainly would.”
Start-ups interested in applying to the third Innovandi Open Challenge, can click here for more information. The deadline for applications is 15th April.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220364304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
